Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study
Björn Pasternak, Viktor Wintzell, Mads Melbye, et al.
BMJ (2020), pp. m1186-m1186
Open Access | Times Cited: 84

Showing 1-25 of 84 citing articles:

Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations
Kevin Yau, Atit Dharia, Ibrahim Alrowiyti, et al.
Kidney International Reports (2022) Vol. 7, Iss. 7, pp. 1463-1476
Open Access | Times Cited: 130
Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
Guntram Schernthaner, Naim Shehadeh, Ametov As, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 127
Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database
Hajime Nagasu, Yuichiro Yano, Hiroshi Kanegae, et al.
Diabetes Care (2021) Vol. 44, Iss. 11, pp. 2542-2551
Open Access | Times Cited: 70
Gender Differences in Diabetic Kidney Disease: Focus on Hormonal, Genetic and Clinical Factors
Annalisa Giandalia, Alfio Edoardo Giuffrida, Guido Gembillo, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 11, pp. 5808-5808
Open Access | Times Cited: 68
Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes
Melanie J. Davies, Heinz Drexel, François R. Jornayvaz, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 44
SGLT2 Inhibitors: The Sweet Success for Kidneys
Atit Dharia, Abid Ali Khan, Vikas S. Sridhar, et al.
Annual Review of Medicine (2023) Vol. 74, Iss. 1, pp. 369-384
Open Access | Times Cited: 29
SGLT2 inhibitor counteracts NLRP3 inflammasome via tubular metabolite itaconate in fibrosis kidney
Qingqing Ke, Caifeng Shi, Yunhui Lv, et al.
The FASEB Journal (2021) Vol. 36, Iss. 1
Closed Access | Times Cited: 53
Association of Sodium-Glucose Cotransporter–2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes
Min Zhuo, Chelsea E. Hawley, Julie M. Paik, et al.
JAMA Network Open (2021) Vol. 4, Iss. 10, pp. e2130762-e2130762
Open Access | Times Cited: 52
SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes
Min Zhuo, Julie M. Paik, Deborah J. Wexler, et al.
American Journal of Kidney Diseases (2021) Vol. 79, Iss. 6, pp. 858-867.e1
Open Access | Times Cited: 51
Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes
Yan Xie, Benjamin Bowe, Andrew K. Gibson, et al.
JAMA Internal Medicine (2021) Vol. 181, Iss. 8, pp. 1043-1043
Open Access | Times Cited: 43
Tubular Cell Glucose Metabolism Shift During Acute and Chronic Injuries
Anna Faivre, Thomas Verissimo, Hannah Auwerx, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 43
Kidney outcomes in patients with diabetes mellitus did not differ between individual sodium-glucose cotransporter-2 inhibitors
Yuta Suzuki, Hidehiro Kaneko, Akira Okada, et al.
Kidney International (2022) Vol. 102, Iss. 5, pp. 1147-1153
Open Access | Times Cited: 34
Defining measures of kidney function in observational studies using routine health care data: methodological and reporting considerations
Juan Jesús Carrero, Edouard L. Fu, Søren Viborg Vestergaard, et al.
Kidney International (2022) Vol. 103, Iss. 1, pp. 53-69
Open Access | Times Cited: 31
Considerations on the use of different comparators in pharmacovigilance: A methodological review
Christopher A. Gravel, Antonios Douros
British Journal of Clinical Pharmacology (2023) Vol. 89, Iss. 9, pp. 2671-2676
Open Access | Times Cited: 22
Sodium‐glucose cotransporter‐2 inhibitors and kidney outcomes in real‐world type 2 diabetes populations: A systematic review and meta‐analysis of observational studies
Anna Forbes, Rebecca Suckling, William Hinton, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 8, pp. 2310-2330
Closed Access | Times Cited: 19
Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk
Gian Paolo Fadini, Enrico Longato, Mario Luca Morieri, et al.
The Lancet Regional Health - Europe (2024) Vol. 38, pp. 100847-100847
Open Access | Times Cited: 7
Sodium glucose co-transporter-2 inhibitors in intensive care unit patients with type 2 diabetes: a pilot case control study
Johan Mårtensson, Salvatore Lucio Cutuli, E Osawa, et al.
Critical Care (2023) Vol. 27, Iss. 1
Open Access | Times Cited: 13
The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
Emily Brown, John Wilding, Uazman Alam, et al.
Annals of Medicine (2020) Vol. 53, Iss. 1, pp. 2072-2089
Open Access | Times Cited: 39
Nephroprotection by SGLT2 Inhibition: Back to the Future?
Luca De Nicola, Francis B. Gabbai, Carlo Garofalo, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 7, pp. 2243-2243
Open Access | Times Cited: 36
Long-Term, Real-World Kidney Outcomes with SGLT2i versus DPP4i in Type 2 Diabetes without Cardiovascular or Kidney Disease
Cheli Melzer Cohen, Meir Schechter, Aliza Rozenberg, et al.
Clinical Journal of the American Society of Nephrology (2023)
Open Access | Times Cited: 12
Comparators in Pharmacovigilance: A Quasi-Quantification Bias Analysis
Christopher A. Gravel, William Bai, Antonios Douros
Drug Safety (2024) Vol. 47, Iss. 8, pp. 809-819
Open Access | Times Cited: 4
Adverse renal events between ranibizumab and aflibercept in patients with diabetic macular oedema in Taiwan: a comparative cohort study
Wan‐Ju Annabelle Lee, Shih‐Chieh Shao, Miyuki Hsing‐Chun Hsieh, et al.
British Journal of Ophthalmology (2025), pp. bjo-325509
Closed Access
Exploring the complexities of disproportionality analysis in pharmacovigilance: reflections on the READUS-PV guideline and a call to action
Tarek A. Hammad, Melissa Naylor, Dona M Ely, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes
David C. Wheeler, June James, Dipesh Patel, et al.
Diabetes Therapy (2020) Vol. 11, Iss. 12, pp. 2757-2774
Open Access | Times Cited: 30
Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes
André Scheen
Diabetes & Metabolism (2021) Vol. 47, Iss. 6, pp. 101275-101275
Closed Access | Times Cited: 26
Page 1 - Next Page

Scroll to top